Huntington Bancshares
HBAN
$16.38
-1.27%
Huntington Bancshares Inc. is a regional bank holding company that provides a comprehensive suite of consumer and commercial banking services, including deposit accounts, lending, payments, investment management, capital markets, equipment financing, and treasury management, operating primarily in the Midwestern United States. The company is a significant player in the regional banking sector, distinguishing itself through a focus on relationship-based banking and a strong commercial lending franchise. The current investor narrative centers on the stock's performance relative to its regional banking peers amid a volatile interest rate environment, with recent price action reflecting concerns about net interest margin pressure and credit quality, as well as the ongoing debate over the bank's ability to navigate economic uncertainty while maintaining its dividend.…
HBAN
Huntington Bancshares
$16.38
Investment Opinion: Should I buy HBAN Today?
Rating & Thesis: HBAN is rated a Hold. The core thesis is that the stock presents compelling value but lacks a near-term catalyst to reverse its negative momentum, requiring investors to patiently wait for earnings to confirm the recovery priced into its forward multiple. This aligns with the mixed but leaning-positive analyst sentiment, though the average target price is not provided for a precise upside calculation.
Supporting Evidence: The primary valuation metric, a forward P/E of 8.56x, is deeply discounted compared to its own trailing multiple of 11.61x and is attractive for a profitable regional bank. The company generates substantial free cash flow ($2.265B TTM) and maintains a solid net margin of 17.7%. However, these strengths are counterbalanced by a 3-month price decline of -10.20% and a sequential drop in quarterly net income, indicating fundamental headwinds.
Risks & Conditions: The two biggest risks are a continuation of the earnings decline and a breakdown below the $15.00 technical support level. This Hold rating would upgrade to a Buy if the forward P/E compressed further toward 7x on sustained earnings growth, or if the stock decisively reclaimed the $18.00 resistance level on strong volume. It would downgrade to a Sell if QoQ net income declines further or if revenue growth decelerates below 3% year-over-year. Based on its historical P/E range and sector comparables, the stock is currently fairly valued to slightly undervalued, with the market discount reflecting justified near-term uncertainties.
Sign up to view all
HBAN 12-Month Price Forecast
The AI assessment is neutral based on the offsetting forces of deep value and weak momentum. The low forward P/E is the most compelling data point, suggesting the market's fears may be overdone. However, the recent earnings volatility and technical breakdown cannot be ignored, indicating the path to a re-rating will be bumpy. Confidence is medium due to the low analyst coverage, which reduces the quality of the consensus view. The stance would upgrade to bullish on a confirmed reversal above $18.00 with improving quarterly earnings trends, or downgrade to bearish on a break below $15.00 accompanied by deteriorating credit metrics.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Huntington Bancshares's 12-month outlook, with a consensus price target around $21.29 and implied upside of +30.0% versus the current price.
Average Target
$21.29
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$13 - $21
Analyst target range
Analyst coverage for HBAN appears limited with only 3 analysts providing estimates, which is low for a company of its size and may indicate it is under-followed by the sell-side, potentially leading to higher volatility and less efficient price discovery. The consensus sentiment, based on recent institutional ratings, is mixed but leans positive, with firms like Morgan Stanley, JP Morgan, and Truist Securities maintaining 'Overweight' or 'Buy' ratings, while Piper Sandler has an 'Underweight' and Barclays and Keefe Bruyette have 'Equal Weight' or 'Market Perform' ratings, reflecting uncertainty about the near-term outlook for regional banks. The average revenue estimate for the next period is approximately $13.06 billion, with a tight range between $13.01 billion and $13.10 billion, and the average EPS estimate is $2.12, ranging from $1.74 to $2.35; the wide EPS range of $0.62 signals significant divergence in earnings expectations among the few covering analysts, highlighting the lack of a strong consensus on the company's profit trajectory in the current economic climate.
Bulls vs Bears: HBAN Investment Factors
The evidence for HBAN presents a classic value versus momentum tension. The bull case is anchored in compelling valuation (8.56x forward P/E), strong cash generation, and solid profitability, suggesting the stock is oversold. The bear case highlights deteriorating technicals, earnings volatility, and uncertain revenue growth. Currently, the bearish momentum and earnings concerns hold stronger evidence, as reflected in the stock's 3-month decline of -10.20%. The single most important tension is whether the anticipated earnings recovery implied by the low forward P/E materializes, or if the sequential decline in net income marks the beginning of a more protracted downturn. The resolution of this earnings trajectory will dictate the stock's direction.
Bullish
- Strong Free Cash Flow Generation: HBAN generated $2.265 billion in trailing twelve-month free cash flow, providing significant financial flexibility. This robust cash generation supports the company's 4.0% dividend yield and potential for share repurchases, offering a tangible return to shareholders.
- Attractive Forward Valuation: The stock trades at a forward P/E of 8.56x, a significant discount to its trailing P/E of 11.61x. This implies the market is pricing in a meaningful earnings recovery, with the forward multiple representing a clear value proposition relative to the financial sector average.
- Solid Profitability Metrics: The company maintains healthy margins, with a Q4 2025 gross margin of 63.17% and an operating margin of 21.53%. A return on equity of 9.08% indicates efficient use of shareholder capital, which is respectable for the regional banking sector.
- Conservative Balance Sheet Leverage: HBAN's debt-to-equity ratio of 0.76 indicates moderate and manageable leverage. This conservative financial structure provides a buffer against economic downturns and reduces refinancing risk in a volatile interest rate environment.
Bearish
- Earnings Volatility and Sequential Decline: Net income fell from $629 million in Q3 2025 to $519 million in Q4 2025, a 17.5% sequential drop. This quarterly earnings volatility, coupled with a wide analyst EPS estimate range of $1.74 to $2.35, signals uncertainty about near-term profit stability.
- Technical Downtrend and Weak Momentum: The stock is down 10.20% over the past three months and trades 16% below its 52-week high, indicating a loss of momentum. A recent max drawdown of -22.06% highlights its susceptibility to sharp sector-wide sell-offs, eroding investor confidence.
- Revenue Growth Pressure: While Q4 revenue grew 5.8% year-over-year, it declined sequentially from Q3. This suggests potential top-line pressure, a critical concern for a bank whose valuation is sensitive to net interest income trends in the current macro environment.
- Low Analyst Coverage and Sentiment Divergence: Only 3 analysts provide estimates, indicating the stock is under-followed, which can lead to inefficient price discovery. Institutional ratings are mixed, with 'Overweight' and 'Buy' ratings countered by 'Underweight' and 'Equal Weight', reflecting a lack of consensus.
HBAN Technical Analysis
The stock has been in a volatile downtrend over the past six months, with the price declining from a high near $19.27 in early February 2026 to a recent close of $16.38, representing a 1-year price change of +27.08% but a more concerning 3-month decline of -10.20%. The current price of $16.38 sits approximately 41% above its 52-week low of $12.48 but 16% below its 52-week high of $19.46, indicating it is in the lower-middle portion of its annual range and has given back a significant portion of its prior gains, suggesting a loss of momentum and potential bearish sentiment taking hold. Recent short-term momentum shows a modest 1-month gain of 4.73%, which contrasts sharply with the negative 3-month performance, signaling a potential oversold bounce or consolidation within the broader downtrend; however, this nascent recovery remains fragile as the stock's 1-month relative strength of +4.27% versus the SPY's +0.46% is a positive divergence that requires confirmation. Key technical support is clearly defined at the 52-week low of $12.48, while immediate overhead resistance lies near the recent highs around $19.46; a sustained break above the $17.50-$18.00 zone would be needed to signal a reversal, while a breakdown below $15.00 could accelerate selling pressure. The stock's beta of 0.974 indicates volatility roughly in line with the broader market, which is typical for a regional bank, but the recent max drawdown of -22.06% highlights the stock's susceptibility to sharp pullbacks during sector-wide sell-offs.
Beta
0.97
0.97x market volatility
Max Drawdown
-22.1%
Largest decline past year
52-Week Range
$13-$19
Price range past year
Annual Return
+27.1%
Cumulative gain past year
| Period | HBAN Return | S&P 500 |
|---|---|---|
| 1m | +4.7% | +2.6% |
| 3m | -10.2% | -2.3% |
| 6m | +5.0% | +2.6% |
| 1y | +27.1% | +27.3% |
| ytd | -6.3% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HBAN Fundamental Analysis
Revenue has shown steady but modest growth, with Q4 2025 revenue of $3.247 billion representing a 5.8% year-over-year increase from the prior-year quarter's $3.069 billion; however, sequential quarterly revenue has been volatile, declining from $3.228 billion in Q3 2025, which suggests potential pressure on top-line expansion. The company remains profitable, reporting net income of $519 million in Q4 2025 with a net margin of 17.7%, though this represents a decline from the $629 million net income in Q3 2025; the gross margin for the latest quarter was a healthy 63.17%, and the operating margin stood at 21.53%, indicating the core banking operations continue to generate solid profitability despite the quarterly earnings fluctuation. The balance sheet appears conservatively managed with a debt-to-equity ratio of 0.76, signaling moderate leverage, and the company generated substantial free cash flow of $2.265 billion on a trailing twelve-month basis; however, the current ratio of 0.19 is very low, which is typical for banks but indicates limited liquid assets relative to short-term liabilities, and the return on equity of 9.08% is respectable for the sector, suggesting efficient use of shareholder capital.
Quarterly Revenue
$3.2B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.63%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HBAN Overvalued?
Given the company's consistent profitability with a positive net income of $519 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 11.61x, while the forward PE is significantly lower at 8.56x, implying the market expects a meaningful improvement in earnings over the next twelve months, likely driven by anticipated stabilization in net interest income and cost management. Compared to typical regional bank valuations, a trailing PE of 11.6x appears to be at a slight discount to the broader financial sector average, which often trades in the low-to-mid teens, suggesting the market is pricing in below-average growth or heightened risk perceptions relative to peers. Historically, the stock's own trailing PE has ranged significantly, from as low as 6.71x in early 2023 to over 18.9x in late 2023; the current multiple of 11.61x sits near the midpoint of this historical range, indicating the stock is neither excessively cheap nor expensive based on its own history, but the discount to its forward PE suggests expectations for earnings recovery are already being factored in.
PE
11.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -268x~19x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HBAN faces risks from earnings volatility, as evidenced by the 17.5% sequential drop in net income from Q3 to Q4 2025. The company's low current ratio of 0.19, while typical for banks, indicates limited liquid assets to cover short-term obligations, potentially increasing vulnerability during a liquidity crisis. Furthermore, revenue growth, while positive year-over-year at 5.8%, showed sequential weakness, suggesting the core banking franchise may be facing margin pressure or slowing loan demand that could hinder top-line expansion.
Market & Competitive Risks: The stock's primary market risk is valuation compression; despite its low forward P/E, the stock trades at a discount due to sector-wide concerns about net interest margins and credit quality. With a beta of 0.974, HBAN's price moves nearly in lockstep with the broader market, offering little defensive diversification during downturns. Competitive and regulatory headwinds for regional banks, including potential increased capital requirements and competition from larger national banks, could further pressure returns and limit growth opportunities.
Worst-Case Scenario: The worst-case scenario involves a severe economic downturn in the Midwestern U.S., leading to a sharp rise in loan defaults, a collapse in net interest margins, and a dividend cut. This could trigger a re-rating to crisis-level valuations, pushing the stock toward its 52-week low of $12.48. From the current price of $16.38, this scenario implies a realistic downside of approximately -24%. A breach of key technical support near $15.00 could accelerate this selling pressure, potentially leading to losses exceeding 30% if sector sentiment turns deeply negative.
FAQ
The key risks are, in order of severity: 1) Earnings & Fundamental Risk: Sequential net income dropped 17.5% last quarter, and revenue growth is modest at 5.8% YoY. 2) Sector & Macro Risk: As a regional bank, it is highly sensitive to interest rate changes and economic cycles (beta 0.974). 3) Technical & Sentiment Risk: The stock is down 10.20% over 3 months and faces selling pressure, with a recent max drawdown of -22.06%. 4) Liquidity Risk: The very low current ratio of 0.19, while standard for banks, indicates reliance on stable funding markets.
The 12-month forecast presents three scenarios. The Base Case (60% probability) targets a range of $16.50 to $18.50, assuming earnings meet the average analyst EPS of $2.12 and volatility subsides. The Bull Case (25% probability) targets $19.46 to $21.00 on faster-than-expected earnings recovery. The Bear Case (15% probability) targets $12.48 to $15.00 if credit deteriorates and earnings miss. The base case is most likely, hinging on the assumption that the U.S. economy avoids a severe recession, allowing HBAN's fundamentals to stabilize.
HBAN appears fairly valued to slightly undervalued based on forward earnings expectations. The forward P/E of 8.56x represents a significant discount to its own trailing P/E of 11.61x, implying the market expects earnings to grow. Compared to the broader financial sector, which often trades in the low-to-mid teens P/E, this multiple is attractive. The valuation implies the market is paying a discount for HBAN due to perceived risks from interest rates and credit quality, but if those risks subside, the stock has room for multiple expansion.
HBAN is a good buy for a specific type of investor: those seeking value and income who have a medium-to-long-term horizon and can withstand sector volatility. The 4.0% dividend yield and low forward P/E of 8.56x provide a margin of safety and income. However, with the stock in a technical downtrend and earnings showing recent volatility, it is not a good buy for short-term traders or those seeking stable, low-risk appreciation. The biggest downside risk is a test of the 52-week low near $12.48, representing a -24% decline.
HBAN is more suitable for a long-term investment horizon of 2-3 years or more. Its value proposition relies on the cyclical recovery of the banking sector and the compounding effect of its 4.0% dividend yield. The stock's beta near 1.0 and recent volatility make it a poor candidate for short-term trading. A long-term horizon allows investors to collect the dividend while waiting for the valuation discount to close as earnings potentially recover. A minimum holding period of 12-18 months is suggested to navigate through the current economic uncertainty.